Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease

Official title

A Phase IIa Open Label, Dose-Finding, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease (PAD)

Overview

The goal of this clinical trial is to study the safety and tolerability of Etrinabdione in adult patients with peripheral arterial disease. It will also learn about the preliminary efficacy of Etrinabdione. The main questions it aims to answer are: Has Etrinabdione an acceptable safety/tolerability profile during 12 months? Do the patients show any improvement in any of the tests included in the protocol for this disease? Researchers will test first the low dose of Etrinadione. If the product is safe at 3 months, the high dose can start. Participants will: Take Etrinabdione twice a day for 12 months. Visit the clinic once every 4 weeks for checkups and tests.

Detailed description

This is a single center, open-label Phase IIa clinical study. The study will be conducted with 2 treatment arms 25 mg BID and 50 mg BID.

The study consists of a Screening Period, a Treatment Period, and a Follow-up Period. Total duration 14 months.

Subjects who meet the inclusion criteria and do not meet the exclusion criteria at screening will start with the lower dose (25 mg BID). When the 12 patients have been treated for 3 months and the PK and safety data are evaluated by the regulatory authority, the Sponsor and the site investigators, the high dose (50 mg BID) will be released.

Interventions

• Drug Etribnabdione 25 mg BID
  The trial will start with the lower dose. When the 12 patients have been treated for 3 months and the PK and safety data are evaluated by the regulatory authority, the Sponsor and the site investigators, the high dose (50 mg BID) will be released.
• Drug Etribnabdione 50 mg BID
  The treatment will start when the regulatory authority, the sponsor and the site investigators have reviewed the low dose safety and pharmacokinetics data.

Primary outcome measures

• Incidence and severity of Treatment Emergent Adverse Events (TEAEs) [Time frame: 13 months]

Secondary outcome measures (6)

• Vascularization [Time frame: Baseline, 6 and 12 months]
• Absolute claudication time [Time frame: Baseline, 3, 6 and 12 months]
• Hemodynamic [Time frame: Baseline, 3, 6 and 12 months]
• Stenosis [Time frame: Baseline, 3, 6 and 12 months]
• Disease specific quality of life questionnaire (VascuQoL-6) [Time frame: Baseline, 3, 6 and 12 months]
• Tissue oxigenation [Time frame: Baseline, 3, 6 and 12 months]

Eligibility criteria

Inclusion criteria

• Willing and able to provide informed consent and capable of understanding and complying with the protocol;
• Subjects classified as critical limb ischemia (CLI) Rutherford Category 2 or 3 (moderate or severe) claudication;
• Diabetes mellitus type 2 with HbA1c < 9%;
• In case of treatment for PAD, the subject is controlled on medical therapy indicated for CLI;
• A female patient is eligible to participate if she is not pregnant, not breastfeeding, and agrees to use a highly effective method of contraception;
• A male patient with a female partner of childbearing potential is eligible if he agrees to use acceptable method of contraception.

Exclusion criteria

• Planned surgical or endovascular revascularization on the index leg within the next 12 months;
• Failed surgical or endovascular revascularization on the index leg within 10 days prior to screening;
• Amputation at or above the talus on the index leg;
• Planned major amputation within the first month after screening;
• On the index leg, use of concomitant wound treatments not currently approved for ischemic wound-healing within 30 days prior to screening or plans to initiate new treatments to the index leg during the trial;
• Uncontrolled or untreated proliferative retinopathy;
• Blood clotting disorder not caused by medication;
• Severe hypertension according to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure;
• Evidence of moderate to severe hepatocellular dysfunction;
• Positive test for human immunodeficiency virus 1 (HIV 1), HIV 2, hepatitis B virus (HBV), hepatitis C virus (HCV) or Treponema Pallidum;
• Subjects who may not be healthy enough to successfully complete all protocol requirements, or who are not expected to survive more than 12 months, or in whom results may be particularly difficult to assess.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

Spain · 1 center

• Hospital Universitario Reina Sofía — Córdoba

Publications

• Garcia-Martin A, Prados ME, Lastres-Cubillo I, Ponce-Diaz FJ, Cerero L, Garrido-Rodriguez M, Navarrete C, Pineda R, Rodriguez AB, Munoz I, Moya J, Medeot A, Moreno JA, Chacon A, Garcia-Revillo J, Munoz E. Etrinabdione (VCE-004.8), a B55alpha activator, promotes angiogenesis and arteriogenesis in critical limb ischemia. J Transl Med. 2024 Nov 6;22(1):1003. doi: 10.1186/s12967-024-05748-w. PMID 39506809

Identifiers

NCT: NCT06774040 · Etrinabdione-PAD02

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗